Lexeo Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
78.6M
on 2026-06-30, from 32.9M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
S-3 of 2024-12-13. Not read yet. S-3 ↗
$75.0M
Leerink Partners, agreement of 2025-03-24. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-12 is not read yet.
Cash
9.6 quarters
$211.7M on 2026-06-30 ÷ $22.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2025-10-16 | Public offering incl. 1.25M pre-funded | 16,875,015 | $8.00 | $125.0M | 424B5 ↗ |
| 2025-10-16 | Private placement incl. 1.25M pre-funded | 2,500,030 | not read | $10.0M | 8-K ↗ |
| 2025-05-27 | Private placement incl. 6.96M pre-funded | 27,753,676 | not read | $80.0M | 8-K ↗ |